You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Mpox after vaccination: a case series
  1. Inês Aparício Martins,
  2. Ana Luísa João,
  3. José Miguel Neves,
  4. Cândida Fernandes
  1. Dermatology and Venereology Department, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal
  1. Correspondence to Dr Inês Aparício Martins, Centro Hospitalar Universitário de Lisboa Central, EPE, Lisboa, 1169-050, Portugal; inesapariciomartins{at}gmail.com

https://doi.org/10.1136/sextrans-2023-056055

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In 2022, in response to the global mpox outbreak, Portugal introduced the Modified Vaccinia Ankara-Bavarian Nordic vaccine for at-risk groups; two intradermal doses were preferred to maximise vaccine availability. We retrospectively reviewed the clinical characteristics of vaccinated and unvaccinated patients diagnosed with mpox at a sexual health clinic in Lisbon …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors IAM contributed to data collection, data analysis and interpretation, and writing of the manuscript. ALJ, JMN and CF contributed to data collection, data analysis and interpretation, and revision of the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.